You are here

  • Home
  • Archive
  • Volume 70, Issue 10
  • Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD

Article metrics

Article menu
Download PDFPDF
Inflammatory bowel disease
Original research
Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD

 

Online download statistics by month:

Online download statistics by month: April 2021 to September 2024

AbstractFullPdf
Apr 202127702755636
May 2021555054731492
Jun 202124122347710
Jul 202122162099509
Aug 202122832241439
Sep 202121832172538
Oct 202119061867407
Nov 202114471417392
Dec 202111521161248
Jan 202212241221275
Feb 2022699700236
Mar 2022751746282
Apr 2022471450167
May 2022442430201
Jun 2022377375184
Jul 2022559534111
Aug 202234432399
Sep 202244542492
Oct 202235934393
Nov 202230928686
Dec 202227625683
Jan 2023274247101
Feb 202323823295
Mar 202335133870
Apr 20233644326
May 20234582518
Jun 20233111810
Jul 2023262137
Aug 2023318108
Sep 20236131411
Oct 20231511179
Nov 20233931912
Dec 2023479165
Jan 2024271249
Feb 20243281111
Mar 20243113023
Apr 20243252612
May 20244531014
Jun 2024215189
Jul 2024288136
Aug 202425668
Sep 20243682218
Total36562287727762